NKTR Drug delivery Company Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company

NKTR 58.41

+0.7%

1:30 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: dalroi who wrote (331)	6/14/2010 4:46:10 PM
From: david nordic	1 Recommendation of 507

Vergote is a gynecologic surgeon subspecialised in onco cases and NOT the oncologist who prescribes the chemotherapy at the KUL Well, Dr Vergote led the Phase IIB program following Dr Dan Van Hoff Phase I. I do not know if a company picks the lead investigator or if the lead investigator picks the drug! Dr Dan Van Hoff won an award at 2010 ASCO. Unrelated to being a NKTR 102 lead investigator. Did Dr Van Hoff choose NKTR 102? Dr Dan Van Hoff comments are just as strong. In his career of 316 investigative compounds, NKTR 102 was the most bio active. Its not what they say but the actual trial results which were superior. ovariancancer.org When this group is following and tracking NKTR 102, it should mean more..... the user has more say.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next